COVID-19 transmission: Study indicates microdroplets do not spread SARS-CoV-2 as efficiently through air
A recent study done in the US suggested that the risk of airborne transmission decreases by half when you double the physical distance and that even simple cloth masks can reduce the risk of transmission
COVID-19 spreads through droplet transmission when a person coughs, sneezes, talks or sings. The bigger droplets fall on the surface of objects, which then act as fomites: high-touch surfaces that can spread the disease. Some smaller droplets stay in the air; it has previously been indicated that SARS-CoV-2 can stay for up to three hours in the air. However, scientists have not yet reached consensus over the occurrence of airborne transmission of the disease.
Recently, the Centers for Disease Control (CDC), USA said that COVID-19 can spread through airborne transmission and affect people even farther than six feet away. Several studies have reached similar conclusions in terms of physical distance.
A recent study done in the US suggested that the risk of airborne transmission decreases by half when you double the physical distance and that even simple cloth masks can reduce the risk of transmission.
However, physical activity increases the breathing rate and when more people are present in an area, it proportionally increases the risk of disease spread.
Now, a study done at the American Institute of Physics indicates that aerosol droplets are not as efficient at spreading the COVID-19 causing virus as we assumed.
The study is published in the journal Physics of Fluid.
Super-spreader events and closed spaces
Various super-spreader events or explosive outbreaks in healthcare or public settings have raised concerns about aerosol or airborne transmission.
Case studies have shown how SARS-CoV-2 spread happens in the direction of ventilation in closed spaces and can infect people sitting or standing farther away from the infected person. Experts suggest that airborne transmission of infections depends on the behaviour and properties of microdroplets.
Since infected people can spread the virus before they start showing symptoms, aerosol transmission (if it happens) is suggested to play a huge role in the spread of the disease.
The latest study
To measure the distribution of respiratory droplets, the researchers asked seven test subjects to cough or talk into a laser beam and used a tiny jet nozzle to create microscopic droplets. Here is what was found:
- The size of the droplets did not change with age, sex, height or weight.
- While coughing, most people produced equal numbers of cough droplets, apart from one person who produced 17 times more volume of liquid than others. The authors indicated that this type of person may be responsible for a superspreading event.
- The volume of saliva produced after coughing was way more (0.07 to 0.05 g) than what was produced during talking (0.003 to 0.001 g).
- Adjusting for the viral particles released during a severe infection (since there is no set limit so far, this was a rough estimate to avoid underestimation of the virus released), it was found that only one in 2,000 microdroplets contain enough virus to spread the disease.
- The speed at which the droplets settle on surfaces would play an important role in airborne transmission.
Risk of infection
The risk of a person getting infected with airborne droplets would depend on their susceptibility and the number of viral droplets inhaled. S
ince they don’t yet know how many viral droplets would lead to SARS-CoV-2 infection in a person, the authors of the study considered it to be the same as the other coronavirus SARS-CoV-1, which is between 10 to 100 PFU (plaque-forming units).
Taking the higher end of this number, the researchers found that an unventilated room with a dimension of 2 X 2 X 2 m3 contaminated with a cough of a single person is safe to be in for about 12 minutes due to low viral particles.
However, in a more ventilated room, the authors noted, the air would get quickly diluted and the risk of transmission would be even less.
Health articles in Firstpost are written by myUpchar.com, India’s first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.
The information provided here is intended to provide free education about certain medical conditions and certain possible treatment. It is not a substitute for examination, diagnosis, treatment, and medical care provided by a licensed and qualified health professional. If you believe you, your child or someone you know suffers from the conditions described herein, please see your health care provider immediately. Do not attempt to treat yourself, your child, or anyone else without proper medical supervision. You acknowledge and agree that neither myUpchar nor firstpost is liable for any loss or damage which may be incurred by you as a result of the information provided here, or as a result of any reliance placed by you on the completeness, accuracy or existence of any information provided herein.
Totti’s father died last month from the coronavirus at 76.
A week ago, competitor Pfizer Inc. announced its own COVID-19 vaccine appeared similarly effective: news that puts both companies on track to seek permission within weeks for emergency use
Coronavirus vaccine: Lancet study suggests Sinovac candidate is safe and effective in phase I and II trials
CoronaVac is an inactivated vaccine (vaccine that contains a virus unable to cause disease) that had earlier shown positive results in mice, primates and rats by producing neutralising antibodies against SARS-CoV-2